BioAtla (BCAB) Operating Leases (2021 - 2026)

BioAtla (BCAB) posted quarterly Operating Leases of $4.5 million for Q1 2026, down 4.99% quarter-over-quarter from $4.8 million in Q4 2025.

BioAtla (BCAB) Operating Leases (2021 - 2026) Analysis & Trends

BioAtla's Operating Leases history runs 6 years deep, the most recent figure standing at $4.5 million for Q1 2026.

In Q1 2026, Operating Leases changed N/A year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $4.5 million (changed N/A YoY), while the FY2025 annual figure was $4.8 million, changed N/A from the prior year.
Operating Leases for Q1 2026 stood at $4.5 million, down from $4.8 million in the prior quarter.
The five-year high for Operating Leases was $5.2 million in Q2 2025, with the low at $415000.0 in Q1 2024.
The 5-year median for Operating Leases is $2.8 million (2022), against an average of $2.9 million.
The sharpest annual moves came in 2022 and 2024: Operating Leases slumped 38.22% in 2022, then slumped 79.88% in 2024.
BioAtla's Operating Leases stood at $2.5 million in 2022, then sank by 66.02% to $836000.0 in 2023, then tumbled by 50.36% to $415000.0 in 2024, then surged by 1050.12% to $4.8 million in 2025, then retreated by 4.99% to $4.5 million in 2026.
Business Quant data shows BCAB's Operating Leases at $4.5 million in Q1 2026, $4.8 million in Q4 2025, and $5.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	BioAtla	5.28 Mn	5.28 Mn	-

Download Data